Cohera Medical, Inc® Named Edison Awards Finalist Cohera Medical Inc.'s TissuGlu® Surgical Adhesive Will Be Recognized at Edison Awards Gala on April 25 in Chicago
PITTSBURGH, Feb. 19, 2013 /PRNewswire/ -- Cohera Medical, Inc. (www.coheramedical.com), a leading innovator and developer of absorbable surgical adhesives and sealants, has been named a 2013 Award Finalist by the internationally renowned Edison Awards™. TissuGlu by Cohera Medical is a Finalist in the Science/Medical – Surgical Aids category, one of twelve categories honored by the Edison Awards. The distinguished awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring creative minds to remain in the forefront of innovation, creativity and ingenuity in the global economy.
"More than any year, this year's slate of Finalists demonstrate the enormous value of teamwork, experimentation, consumer focus, market awareness and game-changing success," said Frank Bonafilia, Edison Awards' executive director. "It's exciting to see companies like Cohera Medical continuing Thomas Edison's legacy of challenging conventional thinking."
"We are honored to be recognized among some of the most innovative companies of today," said Patrick Daly, President & CEO, Cohera Medical. "Our team has always believed this product has the potential to fundamentally change surgical care by eliminating the need for post surgical drains. This award validates our belief that TissuGlu is a 'game-changing' product'.
The ballot of nominees for the Edison Awards is judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge the Finalists' success in meeting the award criteria of Concept, Value, Delivery and Impact. The Panel includes members of the Marketing Executives Networking Group (MENG), the American Association Advertising Agencies (4As) the Chief Marketing Officer Council (CMO), the Design Management Institute (DMI), the American Productivity & Quality Center (APQC) the American Society of Mechanical Engineers (ASME) and the Association of Technology Management & Applied Engineering (ATMAE). Also on the Panel are hundreds of past Edison Award winners, marketing professionals, scientists, designers, engineers and academics.
Award winners will be announced April 25, 2013 at the Edison Awards Annual Gala, held in the Grand Ballroom at historic Navy Pier in Chicago, IL.
The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization dedicated to fostering future innovators. The 2013 Edison Awards are sponsored by Nielsen, Discovery Communications, Science Channel, and USA Today. For more information about the Edison Awards, Edison Universe and a list of past winners, visit www.edisonawards.com.
About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains. TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
Zer0 to 5ive
SOURCE Cohera Medical, Inc.